Pro Medicus (ASX:PME) Research & Development: A$0.0 Mil (TTM As of Dec. 2025)


ASX:PME Pro Medicus Ltd ASX:PME
98 GF Score
Price A$178.99
GF Value A$244.95
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Pro Medicus Research & Development?

Pro Medicus ASX:PME +3.50% 98 Research & Development is A$0.0 Mil as of Dec. 2025. GuruFocus rates ASX:PME with a GF Score™ of 98/100 and a GF Value™ of A$244.95 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Pro Medicus's Research & Development for the six months ended in Dec. 2025 was A$0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.0 Mil.

Pro Medicus  (ASX:PME) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pro Medicus Research & Development Related Terms

Pro Medicus Research & Development Historical Data

* Premium members only.

The historical data trend for Pro Medicus's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pro Medicus Research & Development Chart

Pro Medicus Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pro Medicus Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:PME
98GF Score
Pro Medicus Ltd ASX:PME
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pro Medicus Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$0.0 Mil mean?
Pro Medicus (ASX:PME) has a Research & Development of A$0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Pro Medicus and its competitors.
Is Pro Medicus' Research & Development too high?
Pro Medicus' current Research & Development is A$0.0 Mil. Overall, Pro Medicus has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pro Medicus' Research & Development compare to VEEV and BTSG?
Pro Medicus' Research & Development of A$0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Pro Medicus and its competitors. Pro Medicus's current Research & Development is A$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro Medicus stock overvalued right now?
Based on GuruFocus' analysis, Pro Medicus (ASX:PME) is currently considered Modestly Undervalued. The stock's GF Value™ is A$244.95, compared to a current price of A$178.99 — trading 26.9% below its estimated fair value. The current Research & Development is A$0.0 Mil. Pro Medicus' overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Pro Medicus (ASX:PME), the current Research & Development is A$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pro Medicus (ASX:PME) Overvalued in 2026?

Based on GuruFocus' analysis, Pro Medicus stock appears to be undervalued. The current stock price of A$178.99 is trading 26.9% below its estimated GF Value™ of A$244.95. GuruFocus considers Pro Medicus to be Modestly Undervalued.

Key valuation signals for ASX:PME:

  • Research & Development: A$0.0 Mil
  • GF Value™: A$244.95 vs. price of A$178.99 (26.9% below fair value)
  • GF Score™: 98/100 with 1 warning sign

No single metric tells the full story. See the ASX:PME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pro Medicus Business Description

Address 450 Swan Street, Richmond, VIC, AUS, 3121
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
98GF Score

Get the complete analysis for ASX:PME

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$178.99
Price
A$244.95
GF Value